Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stephen H. Waterman is active.

Publication


Featured researches published by Stephen H. Waterman.


Emerging Infectious Diseases | 2003

Texas Lifestyle Limits Transmission of Dengue Virus

Paul Reiter; Sarah L. Lathrop; Michel L. Bunning; Brad J. Biggerstaff; Daniel E. Singer; Tejpratap Tiwari; Laura Baber; Manuel Amador; Jaime Thirion; Jack Hayes; Calixto Seca; Jorge Mendez; Bernardo Ramirez; Jerome Robinson; Julie A. Rawlings; Vance Vorndam; Stephen H. Waterman; Duane J. Gubler; Gary G. Clark; Edward B. Hayes

Urban dengue is common in most countries of the Americas, but has been rare in the United States for more than half a century. In 1999 we investigated an outbreak of the disease that affected Nuevo Laredo, Tamaulipas, Mexico, and Laredo, Texas, United States, contiguous cities that straddle the international border. The incidence of recent cases, indicated by immunoglobulin M antibody serosurvey, was higher in Nuevo Laredo, although the vector, Aedes aegypti, was more abundant in Laredo. Environmental factors that affect contact with mosquitoes, such as air-conditioning and human behavior, appear to account for this paradox. We conclude that the low prevalence of dengue in the United States is primarily due to economic, rather than climatic, factors.


The Journal of Infectious Diseases | 2010

Mask use, hand hygiene, and seasonal influenza-like illness among young adults: A randomized intervention trial

Allison E. Aiello; Genevra F. Murray; Vanessa Perez; Rebecca M. Coulborn; Brian M. Davis; Monica Uddin; David K. Shay; Stephen H. Waterman; Arnold S. Monto

BACKGROUND During the influenza A(H1N1) pandemic, antiviral prescribing was limited, vaccines were not available early, and the effectiveness of nonpharmaceutical interventions (NPIs) was uncertain. Our study examined whether use of face masks and hand hygiene reduced the incidence of influenza-like illness (ILI). METHODS A randomized intervention trial involving 1437 young adults living in university residence halls during the 2006-2007 influenza season was designed. Residence halls were randomly assigned to 1 of 3 groups-face mask use, face masks with hand hygiene, or control- for 6 weeks. Generalized models estimated rate ratios for clinically diagnosed or survey-reported ILI weekly and cumulatively. RESULTS We observed significant reductions in ILI during weeks 4-6 in the mask and hand hygiene group, compared with the control group, ranging from 35% (confidence interval [CI], 9%-53%) to 51% (CI, 13%-73%), after adjusting for vaccination and other covariates. Face mask use alone showed a similar reduction in ILI compared with the control group, but adjusted estimates were not statistically significant. Neither face mask use and hand hygiene nor face mask use alone was associated with a significant reduction in the rate of ILI cumulatively. CONCLUSIONS These findings suggest that face masks and hand hygiene may reduce respiratory illnesses in shared living settings and mitigate the impact of the influenza A(H1N1) pandemic. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT00490633.


The New England Journal of Medicine | 2017

Persistence of Zika Virus in Body Fluids — Preliminary Report

Gabriela Paz-Bailey; Eli S. Rosenberg; Kate Doyle; Jorge L. Muñoz-Jordán; Gilberto A. Santiago; Liore Klein; Janice Perez-Padilla; Freddy A. Medina; Stephen H. Waterman; Carlos García Gubern; Luisa I. Alvarado; Tyler M. Sharp

Background To estimate the frequency and duration of detectable Zika virus (ZIKV) RNA in human body fluids, we prospectively assessed a cohort of recently infected participants in Puerto Rico. Methods We evaluated samples obtained from 295 participants (including 94 men who provided semen specimens) in whom ZIKV RNA was detected on reverse‐transcriptase–polymerase‐chain‐reaction (RT‐PCR) assay in urine or blood at an enhanced arboviral clinical surveillance site. We collected serum, urine, saliva, semen, and vaginal secretions weekly for the first month and at 2, 4, and 6 months. All specimens were tested by means of RT‐PCR, and serum was tested with the use of anti–ZIKV IgM enzyme‐linked immunosorbent assay. Among the participants with ZIKV RNA in any specimen at week 4, collection continued every 2 weeks thereafter until all specimens tested negative. We used parametric Weibull regression models to estimate the time until the loss of ZIKV RNA detection in each body fluid and reported the findings in medians and 95th percentiles. Results The medians and 95th percentiles for the time until the loss of ZIKV RNA detection were 15 days (95% confidence interval [CI], 14 to 17) and 41 days (95% CI, 37 to 44), respectively, in serum; 11 days (95% CI, 9 to 12) and 34 days (95% CI, 30 to 38) in urine; and 42 days (95% CI, 35 to 50) and 120 days (95% CI, 100 to 139) in semen. Less than 5% of participants had detectable ZIKV RNA in saliva or vaginal secretions. Conclusions The prolonged time until ZIKV RNA clearance in serum in this study may have implications for the diagnosis and prevention of ZIKV infection. In 95% of the men in this study, ZIKV RNA was cleared from semen after approximately 4 months. (Funded by the Centers for Disease Control and Prevention.)BACKGROUND To estimate the frequency and duration of detectable Zika virus (ZIKV) RNA in human body fluids, we prospectively assessed a cohort of newly infected participants in Puerto Rico. METHODS We evaluated samples obtained from 150 participants (including 55 men) in whom ZIKV RNA was detected on reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay in urine or blood in an enhanced arboviral clinical surveillance site. We collected serum, urine, saliva, semen, and vaginal secretions weekly for the first month and then at 2, 4, and 6 months. All specimens were tested by means of RT-PCR, and serum was tested with the use of anti-ZIKV IgM enzyme-linked immunosorbent assay. Among the participants with ZIKV RNA in any specimen at week 4, biweekly collection continued until all specimens tested negative. We used parametric Weibull regression models to estimate the time until the loss of ZIKV RNA detection in each body fluid and reported the findings in medians and 95th percentiles. RESULTS The medians and 95th percentiles for the time until the loss of ZIKV RNA detection were 14 days (95% confidence interval [CI], 11 to 17) and 54 days (95% CI, 43 to 64), respectively, in serum; 8 days (95% CI, 6 to 10) and 39 days (95% CI, 31 to 47) in urine; and 34 days (95% CI, 28 to 41) and 81 days (95% CI, 64 to 98) in semen. Few participants had detectable ZIKV RNA in saliva or vaginal secretions. CONCLUSIONS The prolonged time until ZIKV RNA clearance in serum in this study may have implications for the diagnosis and prevention of ZIKV infection. Current sexual-prevention guidelines recommend that men use condoms or abstain from sex for 6 months after ZIKV exposure; in 95% of the men in this study, ZIKV RNA was cleared from semen after about 3 months. (Funded by the Centers for Disease Control and Prevention.).


Emerging Infectious Diseases | 2007

Deaths from Cysticercosis, United States

Frank Sorvillo; Christopher M. DeGiorgio; Stephen H. Waterman

Most deaths occur among Latino immigrants; US-born persons are affected to a lesser extent.


Morbidity and Mortality Weekly Report | 2016

Local Transmission of Zika Virus — Puerto Rico, November 23, 2015–January 28, 2016

Dana Thomas; Tyler M. Sharp; Jomil Torres; Paige A. Armstrong; Jorge L. Muñoz-Jordán; Kyle R. Ryff; Alma Martinez-Quiñones; José Arias-Berríos; Marrielle Mayshack; Glenn J. Garayalde; Sonia Saavedra; Carlos A. Luciano; Miguel Valencia-Prado; Stephen H. Waterman; Brenda Rivera-Garcia

Zika virus, a mosquito-borne flavivirus, spread to the Region of the Americas (Americas) in mid-2015, and appears to be related to congenital microcephaly and Guillain-Barré syndrome (1,2). On February 1, 2016, the World Health Organization (WHO) declared the occurrence of microcephaly cases in association with Zika virus infection to be a Public Health Emergency of International Concern.* On December 31, 2015, Puerto Rico Department of Health (PRDH) reported the first locally acquired (index) case of Zika virus disease in a jurisdiction of the United States in a patient from southeastern Puerto Rico. During November 23, 2015-January 28, 2016, passive and enhanced surveillance for Zika virus disease identified 30 laboratory-confirmed cases. Most (93%) patients resided in eastern Puerto Rico or the San Juan metropolitan area. The most frequently reported signs and symptoms were rash (77%), myalgia (77%), arthralgia (73%), and fever (73%). Three (10%) patients were hospitalized. One case occurred in a patient hospitalized for Guillain-Barré syndrome, and one occurred in a pregnant woman. Because the most common mosquito vector of Zika virus, Aedes aegypti, is present throughout Puerto Rico, Zika virus is expected to continue to spread across the island. The public health response in Puerto Rico is being coordinated by PRDH with assistance from CDC. Clinicians in Puerto Rico should report all cases of microcephaly, Guillain-Barré syndrome, and suspected Zika virus disease to PRDH. Other adverse reproductive outcomes, including fetal demise associated with Zika virus infection, should be reported to PRDH. To avoid infection with Zika virus, residents of and visitors to Puerto Rico, particularly pregnant women, should strictly follow steps to avoid mosquito bites, including wearing pants and long-sleeved shirts, using permethrin-treated clothing and gear, using an Environmental Protection Agency (EPA)-registered insect repellent, and ensuring that windows and doors have intact screens.


Morbidity and Mortality Weekly Report | 2016

Update: Ongoing Zika Virus Transmission — Puerto Rico, November 1, 2015–July 7, 2016

Laura Adams; Melissa Bello-Pagan; Matthew Lozier; Kyle R. Ryff; Carla Espinet; Jomil Torres; Janice Perez-Padilla; Mitchelle Flores Febo; Emilio Dirlikov; Alma Martinez; Jorge L. Muñoz-Jordán; M. García; Marangely Olivero Segarra; Graciela Malave; Aidsa Rivera; Carrie K. Shapiro-Mendoza; Asher Rosinger; Matthew J. Kuehnert; Koo-Whang Chung; Lisa L Pate; Angela Harris; Ryan R. Hemme; Audrey Lenhart; Gustavo Aquino; Sherif R. Zaki; Jennifer S. Read; Stephen H. Waterman; Luisa I. Alvarado; Francisco Alvarado-Ramy; Miguel Valencia-Prado

Zika virus is a flavivirus transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes, and infection can be asymptomatic or result in an acute febrile illness with rash (1). Zika virus infection during pregnancy is a cause of microcephaly and other severe birth defects (2). Infection has also been associated with Guillain-Barré syndrome (GBS) (3) and severe thrombocytopenia (4,5). In December 2015, the Puerto Rico Department of Health (PRDH) reported the first locally acquired case of Zika virus infection. This report provides an update to the epidemiology of and public health response to ongoing Zika virus transmission in Puerto Rico (6,7). A confirmed case of Zika virus infection is defined as a positive result for Zika virus testing by reverse transcription-polymerase chain reaction (RT-PCR) for Zika virus in a blood or urine specimen. A presumptive case is defined as a positive result by Zika virus immunoglobulin M (IgM) enzyme-linked immunosorbent assay (MAC-ELISA)* and a negative result by dengue virus IgM ELISA, or a positive test result by Zika IgM MAC-ELISA in a pregnant woman. An unspecified flavivirus case is defined as positive or equivocal results for both Zika and dengue virus by IgM ELISA. During November 1, 2015-July 7, 2016, a total of 23,487 persons were evaluated by PRDH and CDC Dengue Branch for Zika virus infection, including asymptomatic pregnant women and persons with signs or symptoms consistent with Zika virus disease or suspected GBS; 5,582 (24%) confirmed and presumptive Zika virus cases were identified. Persons with Zika virus infection were residents of 77 (99%) of Puerto Ricos 78 municipalities. During 2016, the percentage of positive Zika virus infection cases among symptomatic males and nonpregnant females who were tested increased from 14% in February to 64% in June. Among 9,343 pregnant women tested, 672 had confirmed or presumptive Zika virus infection, including 441 (66%) symptomatic women and 231 (34%) asymptomatic women. One patient died after developing severe thrombocytopenia (4). Evidence of Zika virus infection or recent unspecified flavivirus infection was detected in 21 patients with confirmed GBS. The widespread outbreak and accelerating increase in the number of cases in Puerto Rico warrants intensified vector control and personal protective behaviors to prevent new infections, particularly among pregnant women.


Emerging Infectious Diseases | 2003

The U.S.-Mexico Border Infectious Disease Surveillance Project: Establishing Binational Border Surveillance

Michelle Weinberg; Stephen H. Waterman; Carlos Alvarez Lucas; Verónica Carrión Falcón; Pablo Kuri Morales; Luis Anaya Lopez; Chris Peter; Alejandro Escobar Gutiérrez; Ernesto Ramirez Gonzalez; Ana Flisser; Ralph T. Bryan; Enrique Navarro Valle; Alfonso Rodriguez; Gerardo Alvarez Hernandez; Cecilia Rosales; Javier Arias Ortiz; Michael Landen; Hugo Vilchis; Julie A. Rawlings; Francisco Lopez Leal; Luis Ortega; Elaine W. Flagg; Roberto Tapia Conyer; Martin S. Cetron

In 1997, the Centers for Disease Control and Prevention, the Mexican Secretariat of Health, and border health officials began the development of the Border Infectious Disease Surveillance (BIDS) project, a surveillance system for infectious diseases along the U.S.-Mexico border. During a 3-year period, a binational team implemented an active, sentinel surveillance system for hepatitis and febrile exanthems at 13 clinical sites. The network developed surveillance protocols, trained nine surveillance coordinators, established serologic testing at four Mexican border laboratories, and created agreements for data sharing and notification of selected diseases and outbreaks. BIDS facilitated investigations of dengue fever in Texas-Tamaulipas and measles in California–Baja California. BIDS demonstrates that a binational effort with local, state, and federal participation can create a regional surveillance system that crosses an international border. Reducing administrative, infrastructure, and political barriers to cross-border public health collaboration will enhance the effectiveness of disease prevention projects such as BIDS.


Emerging Infectious Diseases | 2004

Cysticercosis-related Deaths, California

Frank Sorvillo; Lawrence Portigal; Christopher M. DeGiorgio; Lisa V. Smith; Stephen H. Waterman; George W. Berlin; Lawrence R. Ash

Cysticercosis is an increasingly important disease in the United States, but information on the occurrence of related deaths is limited. We examined data from California death certificates for the 12-year period 1989–2000. A total of 124 cysticercosis deaths were identified, representing a crude 12-year death rate of 3.9 per million population (95% confidence interval [CI] 3.2 to 4.6). Eighty-two (66%) of the case-patients were male; 42 (34%) were female. The median age at death was 34.5 years (range 7–81 years). Most patients (107, 86.3%) were foreign-born, and 90 (72.6%) had emigrated from Mexico. Seventeen (13.7%) deaths occurred in U.S.-born residents. Cysticercosis death rates were higher in Latino residents of California (13.0/106) than in other racial/ethnic groups (0.4/106), in males (5.2/106) than in females (2.7/106), and in persons >14 years of age (5.0/106). Cysticercosis is a preventable cause of premature death, particularly among young Latino persons in California and may be a more common cause of death in the United States than previously recognized.


Morbidity and Mortality Weekly Report | 2016

Incidence of Zika Virus Disease by Age and Sex — Puerto Rico, November 1, 2015–October 20, 2016

Matthew Lozier; Laura Adams; Mitchelle Flores Febo; Jomil Torres-Aponte; Melissa Bello-Pagan; Kyle R. Ryff; Jorge L. Muñoz-Jordán; M. García; Aidsa Rivera; Jennifer S. Read; Stephen H. Waterman; Tyler M. Sharp; Brenda Rivera-Garcia

Zika virus is a flavivirus transmitted primarily by Aedes species mosquitoes; symptoms of infection include rash, arthralgia, fever, and conjunctivitis.*,† Zika virus infection during pregnancy can cause microcephaly and other serious brain anomalies (1), and in rare cases, Zika virus infection has been associated with Guillain-Barré syndrome (2) and severe thrombocytopenia (3). This report describes the incidence of reported symptomatic Zika virus disease in the U.S. territory of Puerto Rico by age and sex. During November 1, 2015-October 20, 2016, 62,500 suspected Zika virus disease cases were reported to the Puerto Rico Department of Health (PRDH); 29,345 (47%) were confirmed by reverse transcription-polymerase chain reaction (RT-PCR) testing, or were presumptively diagnosed based on serological testing. The highest incidence among confirmed or presumptive cases occurred among persons aged 20-29 years (1,150 cases per 100,000 residents). Among 28,219 (96.2%) nonpregnant patients with confirmed or presumptive Zika virus disease, incidence was higher among women (936 per 100,000 population) than men (576 per 100,000) for all age groups ≥20 years, and the majority (61%) of reported Zika virus disease cases occurred in females. Among suspected Zika virus disease cases in nonpregnant adults aged ≥40 years, the percentage that tested positive among females (52%) was higher than that among males (47%) (p<0.01). Reasons for the higher incidence of Zika virus disease among women aged ≥20 years are not known; serosurveys of persons living near confirmed Zika virus disease cases might help to elucidate these findings. Residents of and travelers to Puerto Rico should remove or cover standing water, practice mosquito abatement, employ mosquito bite avoidance behaviors, take precautions to reduce the risk for sexual transmission, and seek medical care for any acute illness with rash or fever.


Influenza and Other Respiratory Viruses | 2013

Seroepidemiologic investigation of an outbreak of pandemic influenza A H1N1 2009 aboard a US Navy Vessel—San Diego, 2009

Christina B. Khaokham; Monica U. Selent; Fleetwood Loustalot; Shauna Mettee Zarecki; Douglas Harrington; Eileen Hoke; Dennis J. Faix; Ryan G. Ortiguerra; Bryan Alvarez; Nathaniel Almond; Kellie McMullen; Betsy L. Cadwell; Timothy M. Uyeki; Patrick J. Blair; Stephen H. Waterman

During summer 2009, a US Navy ship experienced an influenza‐like illness outbreak with 126 laboratory‐confirmed cases of pandemic influenza A (H1N1) 2009 virus among the approximately 2000‐person crew.

Collaboration


Dive into the Stephen H. Waterman's collaboration.

Top Co-Authors

Avatar

Tyler M. Sharp

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jorge L. Muñoz-Jordán

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Aiden K. Varan

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Frank Sorvillo

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jennifer S. Read

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Aidsa Rivera

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Dana Thomas

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Daniel B. Fishbein

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Harold S. Margolis

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Janice Perez-Padilla

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge